NCT02002832 - A Clinical Trial of Lurasidone in Treatment of Schizophrenia | Biotech Hunter

Enrollment

388

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

November 30, 2015

Conditions

Schizophrenia

Interventions

DRUG

Lurasidone tablets

Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)

DRUG

Risperidone tablets

Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)

Trial Locations (15)

100088

Capital Medical University Affiliated Beijing Anding Hospital, Beijing

100096

Beijing Huilongguan Hospital, Beijing

100191

Peking University Sixth Hospital, Beijing

200030

Shanghai Mental Health Center, Shanghai

210029

Nanjing Brain Hospital, Nanjing

214000

Wuxi Mental Health Center, Wuxi

300222

Tianjin Anding Hospital, Tianjin

410000

The Second Xiangya Hospital of Central South University, Changsha

410007

Hunan Province Brain Hospital, Changsha

453002

Henan Provincial Mental Hospital, Xinxiang

510370

Guangzhou Brain Hospital, Guangzhou

610041

West China Hospital, Sichuan University, Chengdu

650032

First Affiliated Hospital of Kunming Medical University, Kunming

710061

Xi'an Mental Health Center, Xi’an

071000

HeBei Mental Health Center, Baoding

All Listed Sponsors

lead

Sumitomo Pharma (Suzhou) Co., Ltd.

INDUSTRY